Pharm

Abatacept

search

Abatacept, CTLA4-Ig

  • Mechanism
  1. Extracellular CTLA4 fused to Fc of IgG1
  2. Inhibits CD28 to CD80/CD66 binding
  3. Increases T-Cell Activation threshold and inhibits T-Cell proliferation
  • Dosing
  1. IV infusion: 10 mg/kg to 500, 750 or 1000 mg over 30 minutes
  2. Initial: 0, 2 and 4 months and then every 4 months
  • Indications
  • Contraindications
  1. Do not use with TNF antagonist agent, and probably Anankira
  2. Live virus Vaccine within the last 3 months